Log in

NASDAQ:ESTA - Establishment Labs Stock Price, Forecast & News

$25.45
-0.11 (-0.43 %)
(As of 12/16/2019 09:12 AM ET)
Today's Range
$25.23
Now: $25.45
$25.72
50-Day Range
$18.27
MA: $22.54
$26.36
52-Week Range
$16.55
Now: $25.45
$30.06
Volume110,241 shs
Average Volume87,516 shs
Market Capitalization$524.27 million
P/E RatioN/A
Dividend YieldN/A
Beta0.48
Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic plastic surgery and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Divina 3D simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and distributes Puregraft line of products that is used to remove blood, lipids, and other components from adipose tissue. Read More…

Industry, Sector and Symbol

Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ESTA
CUSIPN/A
CIKN/A
Phone506 2434 2400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$61.21 million
Book Value$3.38 per share

Profitability

Net Income$-21,100,000.00

Miscellaneous

Employees505
Market Cap$524.27 million
Next Earnings Date3/18/2020 (Estimated)
OptionableNot Optionable

Receive ESTA News and Ratings via Email

Sign-up to receive the latest news and ratings for ESTA and its competitors with MarketBeat's FREE daily newsletter.


Establishment Labs (NASDAQ:ESTA) Frequently Asked Questions

What is Establishment Labs' stock symbol?

Establishment Labs trades on the NASDAQ under the ticker symbol "ESTA."

How were Establishment Labs' earnings last quarter?

Establishment Labs Holdings Inc (NASDAQ:ESTA) announced its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.62) EPS for the quarter, missing the Zacks' consensus estimate of ($0.51) by $0.11. The business earned $22.85 million during the quarter, compared to the consensus estimate of $20 million. Establishment Labs had a negative return on equity of 75.10% and a negative net margin of 52.76%. View Establishment Labs' Earnings History.

When is Establishment Labs' next earnings date?

Establishment Labs is scheduled to release their next quarterly earnings announcement on Wednesday, March 18th 2020. View Earnings Estimates for Establishment Labs.

What guidance has Establishment Labs issued on next quarter's earnings?

Establishment Labs updated its FY 2019 Pre-Market earnings guidance on Monday, November, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $$86-87 million, compared to the consensus revenue estimate of $$85.39 million.

What price target have analysts set for ESTA?

3 analysts have issued 12-month target prices for Establishment Labs' stock. Their forecasts range from $29.00 to $40.00. On average, they anticipate Establishment Labs' share price to reach $35.33 in the next year. This suggests a possible upside of 38.8% from the stock's current price. View Analyst Price Targets for Establishment Labs.

What is the consensus analysts' recommendation for Establishment Labs?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Establishment Labs in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Establishment Labs.

What are Wall Street analysts saying about Establishment Labs stock?

Here are some recent quotes from research analysts about Establishment Labs stock:
  • 1. According to Zacks Investment Research, "Establishment Labs Holdings Inc. is a medical technology company. It focuses on designing, developing, manufacturing and marketing portfolio of silicone gel-filled breast implants ae well as body shaping implants. The company's brand consists of Motiva Implants(R) and MotivaImagine (R) platform. Its technologies portfolio includes Divina 3D Simulation System(R), Puregraft and MotivaImagine Centers (R). Establishment Labs Holdings Inc. is based in NEW YORK. " (11/4/2019)
  • 2. BTIG Research analysts commented, "Establishment reported impressive Q1 sales of ~$21M, besting consensus of $18M. Heading into the quarter, we felt there was a very strong likelihood of a beat but the magnitude of the sequential bump (27%) was surprising. We are encouraged that quarterly improvement was spurred by strong underlying demand in W. Europe, Brazil, and S. Korea – less so, it seems from any pull forward benefit in Q1. Even with a strong start, guidance was set at $80-84M for FY19, implying little improvement over Q1 results. We understand the conservatism around quarterly lumpiness and seasonality, but we still see a few areas that can drive upside, particularly in the second half: 1) the ramp in 2) ongoing transition to direct sales, and 3) share gains in W. Europe following the fall-out of textured implants. We model FY19 revenue above guidance at $86M." (5/16/2019)

Has Establishment Labs been receiving favorable news coverage?

News articles about ESTA stock have trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Establishment Labs earned a news sentiment score of -1.7 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Establishment Labs.

Are investors shorting Establishment Labs?

Establishment Labs saw a increase in short interest in November. As of November 29th, there was short interest totalling 744,400 shares, an increase of 14.7% from the November 14th total of 649,100 shares. Based on an average trading volume of 94,800 shares, the short-interest ratio is presently 7.9 days. Approximately 4.7% of the shares of the stock are short sold. View Establishment Labs' Current Options Chain.

Who are some of Establishment Labs' key competitors?

What other stocks do shareholders of Establishment Labs own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Establishment Labs investors own include Sientra (SIEN), athenahealth (ATHN), Evolus (EOLS), Allergan (AGN), Conduent (CNDT), Chevron (CVX), Johnson & Johnson (JNJ), Thermo Fisher Scientific (TMO), iShares Core MSCI EAFE ETF (IEFA) and Cboe Global Markets (CBOE).

Who are Establishment Labs' key executives?

Establishment Labs' management team includes the folowing people:
  • Mr. Juan Jose Chacon Quiros, Founder, CEO & Exec. Director (Age 47)
  • Mr. Salvador Santos Dada, Chief Operating Officer (Age 37)
  • Mr. Eddie De Oliveira, VP of Sales, Brazil (Age 36)
  • Ms. Renee M. Gaeta, Chief Financial Officer (Age 38)
  • Mr. Roberto De Mezerville, Chief Technology Officer (Age 39)

When did Establishment Labs IPO?

(ESTA) raised $50 million in an IPO on Thursday, July 19th 2018. The company issued 3,100,000 shares at a price of $15.00-$17.00 per share. Jefferies and Cowen acted as the underwriters for the IPO and BTIG was co-manager.

Who are Establishment Labs' major shareholders?

Establishment Labs' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (0.20%), Berkshire Asset Management LLC PA (0.06%) and Barclays PLC (0.02%). Company insiders that own Establishment Labs stock include David L Bonvenuto, Jw Asset Management, Llc and Nicholas Sheridan Lewin. View Institutional Ownership Trends for Establishment Labs.

Which major investors are selling Establishment Labs stock?

ESTA stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC. View Insider Buying and Selling for Establishment Labs.

Which major investors are buying Establishment Labs stock?

ESTA stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC and Berkshire Asset Management LLC PA. Company insiders that have bought Establishment Labs stock in the last two years include David L Bonvenuto, Jw Asset Management, Llc and Nicholas Sheridan Lewin. View Insider Buying and Selling for Establishment Labs.

How do I buy shares of Establishment Labs?

Shares of ESTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Establishment Labs' stock price today?

One share of ESTA stock can currently be purchased for approximately $25.45.

How big of a company is Establishment Labs?

Establishment Labs has a market capitalization of $524.27 million and generates $61.21 million in revenue each year. The company earns $-21,100,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis. Establishment Labs employs 505 workers across the globe.View Additional Information About Establishment Labs.

What is Establishment Labs' official website?

The official website for Establishment Labs is http://www.establishmentlabs.com/.

How can I contact Establishment Labs?

Establishment Labs' mailing address is Building B15 and 25 Coyol Free Zone, Alajuela G2, . The company can be reached via phone at 506 2434 2400 or via email at [email protected]


MarketBeat Community Rating for Establishment Labs (NASDAQ ESTA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  63 (Vote Outperform)
Underperform Votes:  65 (Vote Underperform)
Total Votes:  128
MarketBeat's community ratings are surveys of what our community members think about Establishment Labs and other stocks. Vote "Outperform" if you believe ESTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ESTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel